Expanding the reach of TIL therapy

We are a biotechnology company pioneering engineered tumor infiltrating lymphocyte (“TIL”) therapies to deliver transformative outcomes for patients suffering from solid tumor malignancies.

We engineer cytoTIL™ therapies using our proprietary cytoDRiVE® platform technology to express regulated therapeutic proteins to enhance anti-tumor activity.

Authors

Priyanka Ajit Joshi

Associate Scientist

Priyanka Ajit Joshi is an Associate Scientist in Analytical Development specializing in cell therapy analytics, including potency assays, flow cytometry, immune profiling, and product characterizat... Read more »

❮ ❯